News and Press Releases

Media Center

Think Globally. Act Locally.

Selio lung biopsy device exemplifies medtech growth and scale

SelioColm McGarvey and Garrett Ryan are eliminating collapsed lung complications

Reposted by InterSearch Ireland


The Irish medtech sector consistently punches above its weight. It helps that 19 of the top 25 global companies covering the field of medical devices, diagnostics and software development are based in Ireland. It has been a crucial factor in fostering a vibrant start-up community that has broadened the manufacturing mix, while 50% of the 450 medtech companies in the Republic are now homegrown.

Selio co-founders Colm McGarvey and Dr Garrett Ryan: based in Trinity College Dublin, their novel medical device will transform lung biopsy procedures by eliminating collapsed lungs.(Source: )

Selio, based in Trinity College Dublin, is an example of what is emerging as a consequence of an ecosystem that is nurturing innovation. Backed by the right supports, it is set on a path towards commercialisation.

It has developed a novel medical device that will transform lung biopsy procedures by eliminating a complication in the form of a collapsed lung (pneumothorax), which is common, costly and dangerous. This new treatment could prevent approximately 121,000 extra hospital admissions yearly; saving healthcare costs of over €1 billion globally.

Selio may still be made up by just two people, Colm McGarvey and Dr Garrett Ryan, but it has cleared big hurdles within a short period and early endorsement has come with a series of innovation awards.

A collapsed lung occurs when the lung biopsy needle pierces the lung and air escapes into the chest cavity. This substantially increases the cost of care by converting an outpatient procedure to one requiring hospitalisation, explains McGarvey – its frequency is stark; arising in some 33 per cent of cases.

He outlines the significance of their product in the context of lung cancer; the most common cancer worldwide – with over 1.8 million cases diagnosed globally, including about 2,300 Irish cases every year. Lung biopsies are the most common method for diagnosis – by way of transthoracic needle biopsy (TTNB) but they can be hazardous because of collapsed lung risk.


For more on this, please click on the link below


Related Story: 

Biopsy Devices Market Worth 2.42 Billion USD by 2022


Clanwilliam Group Acquires Medisec Software to Support NHS Digitisation Push

healthcare digitisationAs part of an effort to spend €100m in the medtech sector, Dublin-based Clanwilliam Group has acquired the UK firm Medisec Software.

Reposted by InterSearch Ireland



In its 13th medtech acquisition of the past three years, the Clanwilliam Group has announced the purchase of the UK firm Medisec Software, a company firmly embedded within the country’s National Health Service (NHS)

Medisec Software, which has been working with NHS organisations for 25 years to digitise clinical correspondence and dictation, has been acquired by Clanwilliam Group. It has become the 13th healthcare technology company to join the group in the last three years.

Some 15,000 primary and secondary healthcare professionals in England currently rely on Medisec products. This includes a number of prominent NHS organisations in the Midlands and North of England working with the technology specialist to help improve care efficiency and speed up crucial information flows.

Being part of Clanwilliam Group will help Medisec to spread its reach to other parts of the country, whilst at the same time retaining its organisational independence to allow the company to continue to provide a consistent service to its existing strong base of customers in the NHS.

Current customers include high profile foundation trust hospitals such as Countess of Chester Hospital NHS Foundation Trust, Alder Hey Children’s NHS Foundation Trust and City Hospitals Sunderland NHS Foundation Trust, and a range of other organisations across different care settings, which collectively generate more than 5 million documents every year using Medisec technology.

Ceri Rothwell, managing director at Medisec Software, said: “This is a tremendous opportunity to expand and improve the ways we support the NHS, at a crucial time of digital transformation in the health service.

“Joining Clanwilliam Group will allow Medisec to access a huge wealth of experience, technical expertise and resource as we work alongside other health technology providers in the group, exploring integration and collaboration opportunities. At the same time we will retain our distinct leadership, our experienced teams and the trusted brand that Medisec customers rely on.”

All Medisec customers can expect business as usual for contracts, support and contact information, which will all remain unchanged following the acquisition. It is also anticipated collaboration with the expansive network in the group will help to significantly boost Medisec’s product development into the future.

Other businesses within Clanwilliam Group include Bluespier, Maxwell Stanley Consulting, Clanwilliam Health, Toniq, Medical Business Systems, Medical Management Services, Claimsure and Epic Solutions.

The group has so far invested £9.5m into technology companies serving the NHS within the last 14 months. This includes Bluespier, which provides trusts with theatre management systems and clinical software, and Maxwell Stanley Consulting, a specialist consultancy firm that helps NHS organisations enhance patient information and financial outcomes through tailored services across clinical coding departments.

Businesses under Clanwilliam Group are now helping to reduce the deficit in NHS trusts by approximately £14m annually.

Howard Beggs, CEO of Clanwilliam Group said: “Clanwilliam Group’s growth strategy across the UK is to actively develop a group of highly synergistic healthcare technology and services businesses. We back leadership, and select companies who are already driving innovation in the healthcare industry and which, with the right support, have the potential to transform the healthcare landscape even further.

“All companies within the group remain independently committed to developing their respective flagship products and services, but as part of Clanwilliam Group, each benefits from synergies of shared knowledge and expertise, that can in turn be passed on to customers and ultimately patients.

“Medisec Software is an instant fit, providing cleverly integrated technologies with a long-term commitment to helping NHS organisations through their digital transformation. We are looking forward to working with Ceri and her team to build on the success already achieved.”

The acquisition of Medisec Software by Clanwilliam Group was brokered by Benchmark International.


For more on this, please click on the link below




servicesSource: Written by Business World

Reposted by InterSearch Ireland



Growth in Ireland's services sector ticked up in July, a survey showed on Thursday, with strong growth in new orders suggesting momentum in the EU's fastest-growing economy continued into the third quarter.

The Investec Services Purchasing Managers' Index (PMI) rose to 58.3 in July from 57.6 in June, when it had slipped to a seven-month low but still remained far above the 50 mark that separates growth from contraction.

The sector last fell below that mark in June 2012, when Ireland was halfway through a three-year bailout. Like the wider economy, services firms have so far proved very resilient to neighbouring Britain's decision to leave the European Union.

The further expansion in July was driven by a faster pace of growth in new business, where the sub-index rebounded back above the 60 mark to 60.4 last month from 57.9 in June.

"Even more encouragingly, the new export orders component reveals broad growth in demand, with respondents reporting higher new orders from a range of markets including the UK, U.S. and Continental Europe," Investec Ireland chief economist Philip O'Sullivan said.

"Services firms have been responding to this by hiring more staff. Indeed, some panellists reported that they are training new staff in line with anticipations of further increases in workloads."

O'Sullivan said that while more than nine times as many firms expect activity to grow over the coming year versus those who foresee a decline, the survey showed that expectations among companies weakened to an eight-month low in July, particularly among travel and leisure operators.

"It is possible that speculation around Ireland's future (post-Brexit) trading relationship with the UK could be slightly dampening the mood here, as that component is more reliant on UK business than the other parts of the industry," O'Sullivan said.

The number of visitors from Britain fell by 6% year-on-year in the first six months of 2017, data showed last week, but the weakness in Ireland's main tourism market has so far been more than offset by growth elsewhere. (Reuters)


For more on this please click on the link below

BioMarin’s two-year Cork expansion finally complete

BioMarinBioMarin’s Shanbally site has benefited from a makeover, with a major two-year project seeing its footprint now reach 20 acres in Cork.

Written by Gordon Hunt

Reposted by InterSearch Ireland


Pharma giant BioMarin has officially unveiled its new-look Shanbally facility, with an expanded warehouse, new administration and utility offices, a canteen, and conference facilities added in recent months.

Taking two years to complete, the company isn’t quite finished yet, though.

The overall project will allow BioMarin to maximise the flexibility of the site with the expansion of the operational manufacturing capacity.

There are also plans for the installation of a wastewater treatment plant later this year, while three new lab expansions are to be completed by the third quarter of 2018.

BioMarin goes from strength to strength

Jean-Jacques Bienaimé, chair and CEO of BioMarin, said Ireland was “an ideal location” to expand within.

Since opening its doors in 2011, the company has grown to 365 employees in Cork, with an additional 67 people based in Dublin and 2,400 employees globally.

“The team at Shanbally has enabled us to accommodate our growing commercial portfolio and advancing clinical programmes,” said Bienaimé.

“Mostly children, our patients suffer from diseases so rare that the entire afflicted population may number as few as 1,000 worldwide. Often inherited, difficult to diagnose and progressively debilitating, these conditions have, up until now, been largely ignored.

“As we continue to grow in Shanbally, we are looking to recruit the best and brightest in a variety of disciplines to help us continue our inspiring work for patients.”

Lure of biopharma

Ireland is one of the world’s top biopharmaceutical manufacturing locations and it has seen more than €10bn of investment in the last 10 years from global biopharma giants.

There are now around 120 biopharmaceutical operations in the country, out of which 40 are approved by the FDA to produce goods for the pivotal US market.

There are 29,000 people directly employed in the biopharma FDI sector alone, and nine out of the top 10 biopharma giants in the world are manufacturing in Ireland.

“I am delighted that BioMarin continues to consolidate its commitment to its Irish operations in Shanbally,” said Martin Shanahan, CEO of IDA Ireland.

“The company’s presence in Cork strengthens Ireland’s global reputation as a biopharmaceutical industry leader and brings high-quality jobs to countless people across the south-west region.

“We look forward to working closely with the company as it further develops its operations here.”


For more on this, please click the link below.